Navigation Links
Human Genome Sciences Initiates Second Randomized Phase 2 Trial of HGS-ETR1 in Combination With Chemotherapy
Date:12/20/2007

e and great medicine to bring innovative drugs to patients with unmet medical needs.

The HGS clinical development pipeline includes novel drugs to treat hepatitis C, lupus, anthrax disease, cancer and other immune-mediated diseases. The Company's primary focus is rapid progress toward the commercialization of its two key lead drugs, Albuferon(R) (albinterferon alfa- 2b) for hepatitis C and LymphoStat-B(R) (belimumab) for lupus. Phase 3 clinical trials of both drugs are ongoing.

ABthrax(TM) (raxibacumab) is in late-stage development for the treatment of anthrax disease, and the Company is on track to begin the delivery in 2008 of 20,000 doses of ABthrax to the Strategic National Stockpile under a contract entered into with the U.S. Government in June 2006. Other HGS drugs in clinical development include two TRAIL receptor antibodies for the treatment of cancers. The IAP inhibitor AEG40826 is expected to enter Phase 1 clinical trials for the treatment of cancer in early 2008.

For more information about Human Genome Sciences, please visit the Company's web site at http://www.hgsi.com. For more information about HGS-ETR1, see http://www.hgsi.com/products/ETR1.html. Health professionals interested in more information about trials involving HGS products are encouraged to inquire via the Contact Us section of the HGS website, http://www.hgsi.com/products/request.html, or by calling (301) 610-5790, extension 3550.

ABthrax, Albuferon, LymphoStat-B, HGS and Human Genome Sciences are trademarks of Human Genome Sciences, Inc.

HGS Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forw
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3)
2. New Initiative Has Shocking Effect: Thousands of Missourians with Abnormal Chromosome Structures Are Not Human
3. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
4. Human Genome Sciences Announces $40 Million Milestone Payment Related to Albuferon(R) Development
5. Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways With Proliferation and Self-Renewal of Human Embryonic Stem Cells
6. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Partners Conference
7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BioCentury-Thomson Financial Investment Conference
8. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Bear Stearns Conference
9. Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand
10. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Merrill Lynch Conference
11. Premier Research Appoints Global Head of Human Resources

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...v. 24 Sigma-Aldrich Corp... NASDAQ OMX conference on Tuesday, December 1st at... parties may listen via live audio broadcast over ...g m a a ldrich.com/ . Users can click the "W...Sigma-Aldrich: Sigma-Aldrich is a leading Life S...
(Date:11/24/2009)...alif., Nov. 24 NeurogesX...ny focused on developing and commercializing novel...nthony DiTonno, President and Chief Executive Offi...per Jaffray Health Care Conference, to be held Dec...w York, New York. ,, Mr. DiTonno and Stephen G...
(Date:11/24/2009)...ficacy endpoint has been met for patients with adv...,, QUEBEC CITY, Nov. 24 /PRNewswire-FirstCall/ ... (the "Company"), a global biopharmaceutical compa...y announced positive efficacy data from a Phase 2 ...e, AEZS-108 (formerly AN-152), in patients with ad...
(Date:11/24/2009)...Calif., Nov. 24 Genomic ... Randy Scott, Genomic Health,s Executive Chairman,...lth Care Conference in New York City on Tuesday, D... the live and subsequently archived webcast of the...n of Genomic Health,s website at http://investor....
Breaking Biology Technology:NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4Genomic Health to Present at Piper Jaffray Health Care Conference 2
... 15 VION,PHARMACEUTICALS, INC. (Nasdaq: VION ) t...due August 15, 2007 on its 7.75% Convertible Senio...cipal amount of the Notes is $60,million. The Com...suance of,shares of its registered Common Stock. A...es of Common Stock, based on today,s closing bid p...
.... 16 Cancer patients fraught with,flare-ups of pa...sistance,in the form of a new easy-to-use oral dru...s designed to quickly deliver pain medication. Ca...ain: persistent and,breakthrough. Persistent cance... for long periods of time, and often most of the d...
.... 16 Cepheid (Nasdaq:,CPHD) today announced that ...der with Northrop Grumman for the purchase of up t...t cartridges and associated materials. The,anthrax...tems (BDS),installed at United States Postal Servi...agreement covers the USPS fiscal years of 2007 thr...
Other Biology Technology:Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes 2Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes 3Novel Technology Breaks Through Cancer Pain 2Cepheid Enters Into Five-Year Agreement With Northrop Grumman for the Purchase of Anthrax Test Cartridges for Use in United States Postal Service Biohazard Detection Systems 2Cepheid Enters Into Five-Year Agreement With Northrop Grumman for the Purchase of Anthrax Test Cartridges for Use in United States Postal Service Biohazard Detection Systems 3
(Date:11/24/2009)...2009) -- The Wildlife Conservation Society (WCS) a...maining population of Siberian tigers has likely d...aching and habitat loss. , WCS says ...hat needs to be done to protect remaining populati...he report was released by the Siberian Tiger Monit...
(Date:11/24/2009)... research on bacterial communities throughout six ...temporal patterns, suggesting that scientists coul...climate change in the polar regions. The study, pu...nal Academy of Sciences Early Edition, shows that...ynchronously over time, correlating with seasonal ...
(Date:11/23/2009)...ted strain of the deadly superbug MRSAan infection...ticsposes a far greater health threat than previou...cording to a study in the December issue of Emerg...asily picked up in fitness centers, schools, and o...urden of MRSA within hospitals, the report found. ...
Breaking Biology News(10 mins):Report shows dramatic decline in Siberian tigers 2Researchers establish common seasonal pattern among bacterial communities in Arctic rivers 2New study finds MRSA on the rise in hospital outpatients 2Greenberg Traurig Attorney Selected For Massachusetts Life Sciences Collaborative Task Force 55324 1Greenberg Traurig Attorney Selected For Massachusetts Life Sciences Collaborative Task Force 55324 2CareFusion Corp to be Included in S 26P 500 Index 55322 1CareFusion Corp to be Included in S 26P 500 Index 55322 2Help Save a Life Bone Marrow Donor Registry Drive Sept 2 at the Karmanos Cancer Center 55320 1Help Save a Life Bone Marrow Donor Registry Drive Sept 2 at the Karmanos Cancer Center 55320 2Help Save a Life Bone Marrow Donor Registry Drive Sept 2 at the Karmanos Cancer Center 55320 3Help Save a Life Bone Marrow Donor Registry Drive Sept 2 at the Karmanos Cancer Center 55320 4
...asing ocean acidification has often focused on its...ruptions of biological processes in the oceans may... professor of ecology and evolutionary biology at ...xpert in coral reef ecology and marine biodiversit...ogical Responses to Ocean Acidification" at the Fa...
...at may hold clues to improving the success of isle...s, according to a Medical College of Georgia scien...lin-producing cells causing high blood glucose lev...r. Rafal Pacholczyk, an immunologist in the MCG Ce... just received a three-year, $495,000 grant from J...
...ster have designed a gene that produces a thousand...y cells., The findings may help address the prime ...ents, ability to specifically and effectively targ...ts should be able to insert "self-destruct" codes ...ll themselves while healthy cells remain largely u...
Other Biology News:Ocean acidification could have broad effects on marine ecosystems 2High blood sugar's impact on immune system holds clues to improving islet cell transplants 2High blood sugar's impact on immune system holds clues to improving islet cell transplants 3Modified gene targets cancer cells a thousand times more often than healthy cells 2Modified gene targets cancer cells a thousand times more often than healthy cells 3
Rabbit Anti-Human ADAM-12 (Meltrin alpha), carboxy terminal end Antibody, Unconjugated from CEDARLANE Laboratories Limited
Mouse Anti-hnRNP F / H Monoclonal Antibody, Unconjugated, Clone 1G11 from Novus Biologicals
Rabbit Anti-MKK6, phospho (Ser207) Polyclonal Antibody, Unconjugated from Abcam
Custom Oligo Assay Single Locus 1920 samples from Illumina
Biology Products: